ProMIS Neurosciences, Inc. (PMN)
Automate Your Wheel Strategy on PMN
With Tiblio's Option Bot, you can configure your own wheel strategy including PMN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PMN
- Rev/Share 0.0
- Book/Share 0.2718
- PB 1.7588
- Debt/Equity 0.0
- CurrentRatio 3.3644
- ROIC -2.1491
- MktCap 15625433.0
- FreeCF/Share -0.6236
- PFCF -0.7189
- PE -17.8372
- Debt/Assets 0.0
- DivYield 0
- ROE -0.1207
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
ProMIS Neurosciences Announces First Quarter 2025 Financial Results
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer's Disease Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts, May 12, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD) and multiple system atrophy (MSA), today announced financial results for the first quarter ended March 31, 2025. “We made significant progress in the first quarter of 2025, advancing our …
Read More
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Massachusetts, March 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced plans to deliver virtual oral presentations at the 2025 Alzheimer's and Parkison's Disease (AD/PD) International Conference taking place in Vienna, Austria from April 1 - 4, 2025. The oral presentations are available on demand starting on Tuesday, April 1, 2025 at 7:00am C.E.T (2:00am E.T).
Read More
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for Alzheimer's Disease Six-month Interim Results Expected in 1H 2026 with Topline Results Anticipated in 2H 2026 CAMBRIDGE, Massachusetts, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced important progress in the PRECISE-AD Phase 1b clinical trial with the dosing of multiple patients with its lead …
Read More
About ProMIS Neurosciences, Inc. (PMN)
- IPO Date 2007-01-10
- Website https://www.promisneurosciences.com
- Industry Biotechnology
- CEO Mr. Neil K. Warma M.B.A.
- Employees 7